Please provide a synopsis of the article in the link below. The synopsis needs to focus on the goal of the corporate restructuring that Vertex was involved in and your general thought's on the dealing with Eli-Lily.
http://www.prnewswire.com/news-releases/vertex-pharmaceuticals-restructures-agreement-with-eli-lilly-vertex-to-lead-development-of-novel-oral-hepatitis-c-protease-inhibitor-vx-950-73647862.html© BrainMass Inc. brainmass.com June 4, 2020, 1:53 am ad1c9bdddf
Please see the attached file(s) for the complete tutorial.
Vertex Merger Synopsis
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) in its restructured agreement with Eli-Lily is now solely responsible of developing and commercializing VX-950, an oral hepatitis C viral protease inhibitor. The restructuring was a result of Eli-Lily's reprioritizing its research portfolio and Vertex's focus on specialty pharmaceutical markets and desire to retain greater downstream rights on its own compounds.
As a result of the ...
The solution provides a synopsis that focuses on the goal of the corporate restructuring that Vertex was involved in.